Related Experiment Video

Updated: Jun 4, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Combining allografting with mTOR inhibitors for metastatic renal cell cancer

M Bregni, G Vitali, J Peccatori

    Bone Marrow Transplantation
    |February 8, 2011
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
    11:27

    Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

    Published on: April 29, 2014

    Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
    10:27

    Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

    Published on: July 25, 2020

    Related Experiment Videos

    Last Updated: Jun 4, 2026

    A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
    06:38

    A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

    Published on: April 12, 2017

    Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
    11:27

    Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

    Published on: April 29, 2014

    Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
    10:27

    Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

    Published on: July 25, 2020

    Related Concept Videos

    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...

    Articles linked to this work by shared authors, journal, and citation graph.

    Molecular constraints of sarcopenia in the ageing muscle.

    Frontiers in aging·2025

    Observation of New Resonances Decaying to J/ψK^{+} and J/ψϕ.

    Physical review letters·2021

    Angular Analysis of the B^{+}→K^{*+}μ^{+}μ^{-} Decay.

    Physical review letters·2021

    Observation of a New Excited D_{s}^{+} Meson in B^{0}→D^{-}D^{+}K^{+}π^{-} Decays.

    Physical review letters·2021

    Measurement of CP Violation in the Decay B^{+}→K^{+}π^{0}.

    Physical review letters·2021

    Observation of Multiplicity Dependent Prompt χ_{c1}(3872) and ψ(2S) Production in pp Collisions.

    Physical review letters·2021

    GVHD prophylaxis and incidence in contemporary alloHSCT: a large real-world GETH/TC analysis.

    Bone marrow transplantation·2026

    GVHD prophylaxis with PTCy, ATG, PTCy+ATG, or no in vivo T-cell depletion in RIC matched-donor PBSC transplantation for AML and MDS.

    Bone marrow transplantation·2026

    Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party.

    Bone marrow transplantation·2026

    Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation.

    Bone marrow transplantation·2026

    Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: a study from the ALWP/EBMT.

    Bone marrow transplantation·2026

    Pregnancy outcomes in women conceiving after hematopoietic stem cell transplantation versus conventional chemotherapy for childhood or adolescent acute leukemia.

    Bone marrow transplantation·2026

    The Next Frontier in Quantitative Co-Clinical Imaging to Advance Functional Precision Oncology.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    G Protein-Coupled Receptor 68 Promotes the Progression of Triple-Negative Breast Cancer and Cuproptosis Resistance via the MEK/ERK Signaling Pathway.

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026

    Gasotransmitters in cancer metastasis: insights from the biology of carbon monoxide, nitric oxide, and hydrogen sulfide.

    Medical gas research·2026

    T Cell-Derived IFN-γ Activates Ferroptosis in Lacrimal Luminal Ductal Cells via JAK-STAT Signaling in Sjögren's Disease-Related Dry Eye.

    Investigative ophthalmology & visual science·2026

    A guide to transcriptional cyclin-dependent kinases in cancer.

    The FEBS journal·2026

    Post-Ischemic Inhibition of the Mitochondrial Ca2+ Uniporter with Ru265 Protects in Ex Vivo and In Vivo Models of Cerebral Ischemia.

    Clinical science (London, England : 1979)·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us